L26/O-067 Evaluating the efficacy of intraovarian HucMSC-exosome treatment vs PRP: advancing follicular reactivation in women of advanced maternal age
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.067 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von U. Dorofeyeva und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does intraovarian administration of huMSCs-exosomes improve ovarian microenvironment, ovarian function and fertility outcomes in women of advanced maternal age undergoing assisted reproduction (ART) Summary answer Intraovarian HuMSC-exosomes improved AFC, mature oocyte yields, blastocyst development, enhancing ovarian response and providing a time-limited opportunity for fertility improvement in AMA patients. What is known already Ovarian age is classically considered the main cause of female reproductive infertility. Fertility declines with changes in the ovarian microenvironment, a reduction in primordial follicles, increased follicle destruction, reduced mitochondrial activity, increased oxidative stress, changes in extracellular matrix molecules, and the associated ovarian stromal compartment, along with low vascularization. Mesenchymal stem cells (MSCs) and their exosomes are noted for their potential to restore ovarian function. This study examines exosomes from human umbilical cord mesenchymal stem cells (HuMSC-exosomes) for their efficacy in increasing follicle yields and improving hormonal profiles following intraovarian application in women of advanced maternal age. Study design, size, duration A 12-month multicenter study (Nov 2024) evaluated HuMSC-exosomes in improving ovarian function for 52 patients aged 39.8-46.3 years. Participants received 2 ml of HuMSC-exosomes via ultrasound-guided intraovarian injections. Primary endpoint: AMH and FSH levels. Secondary endpoints: oocyte yield, FOI, mature oocyte collection and blastocyst development. Inclusion criteria were Poseidon 3&4, normal karyotype, and previous IVF cycle with poor outcomes. Exclusion criteria included history of chemotherapy, radiotherapy, ovarian endometriomas, pelvic inflammation, and coagulopathy. Participants/materials, setting, methods Women in Poseidon groups 3&4 with poor outcomes in previous IVF cycles received intraovarian HuMSC-exosome. Exosomes, prepared at a certified EU Cell Centre, had uniform quality and concentration. The procedure involved injecting 2 ml of HuMSC-exosomes into each ovary. Exosomes were freshly delivered, hormone levels and follicle counts were monitored every 10-14 days over 90 days and patients were recruited for another IVF cycle between 20 to 65 days post-intervention. Main results and the role of chance Primary outcomes demonstrate increase in AMH levels in 56% of patients, peaking between 20 to 35 days post-procedure. A notable reduction in FSH levels by 26% to 87% was observed in 96% of patients, although levels tended to rise 5 months post-treatment in 61% of patients. AFC increased significantly from 3.97 to 5.29 (p = 0.0074). Secondary outcomes show a non-significant change in gonadotropin dosage and stimulation days. However, pre-trigger E2 levels increased significantly (p = 0.001). Cycle cancellation trends showed improvement, with a reduced rate of oocyte pick-up abandonment and no mature oocytes obtained post-OPU decreased from 21.8% to 2.9%. Significant increases were also noted in oocyte retrieval (OR) (2.19 vs 3.64, p = 0.006), mature oocytes (M2) (1.81 vs 2.82, p = 0.021), fertilization rate (1.44 vs 2.48, p = 0.0080), and blastocyst formation rate (0.39 vs 1.03, p = 0.0392). The treatment showed promising results, with clinical pregnancy rate (CPR) of 62.9%, ongoing pregnancy rate (OPR) of 88.2%. This study of intraovarian HuMSC-exosome treatment demonstrating improvements in ovarian microenvironment, hormonal balance, tissue vascularisation, mitochondrial activity, AFC, number of M2oocytes and blastocyst formation. These findings indicate that intraovarian HuMSC-exosome may contribute to enhanced reproductive outcomes. Limitations, reasons for caution Sample size was limited (n = 52), heterogenity of prior interventions and absence of a randomised control group limit generalisability despite extend follow-up. Wider implications of the findings HucMSC-exosomes could become a novel therapeutic avenue for improving ovarian microenvironment and fertility outcomes, potentially revolutionizing treatments for women with POI and age-related fertility decline. Trial registration number No
Zitieren
APA
Dorofeyeva, U., Pylypenko, N., Pliekhova, O., Semchyshyn, R., Ajdini, A., Zhemela, N., Fedashko, M., Matviiv, H., Sventozelska, T., & Aydin, B. (2026). L26/O-067 Evaluating the efficacy of intraovarian HucMSC-exosome treatment vs PRP: advancing follicular reactivation in women of advanced maternal age. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.067
Vancouver
Dorofeyeva U, Pylypenko N, Pliekhova O, Semchyshyn R, Ajdini A, Zhemela N, et al. L26/O-067 Evaluating the efficacy of intraovarian HucMSC-exosome treatment vs PRP: advancing follicular reactivation in women of advanced maternal age. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.067
BibTeX
@article{Dorofeyeva2026,
author = {Dorofeyeva, U. and Pylypenko, N. and Pliekhova, O. and Semchyshyn, R. and Ajdini, A. and Zhemela, N. and Fedashko, M. and Matviiv, H. and Sventozelska, T. and Aydin, B.},
title = {L26/O-067 Evaluating the efficacy of intraovarian HucMSC-exosome treatment vs PRP: advancing follicular reactivation in women of advanced maternal age},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.067}
}
EUVIMED